Please login to the form below
Pexa-Vec
This page shows the latest Pexa-Vec news and features for those working in and with pharma, biotech and healthcare.
Transgene slumps as viral cancer therapy fails phase 3 trial
Pexa-Vec (pexastimogene devacirepvec) – one of the new class of oncolytic virus therapies (OVT) – didn’t add to the efficacy of therapy when it was added to treatment with ... PHOCUS was testing whether a dose of Pexa-Vec given ahead of Nexavar
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
Other oncolytic viruses are coming through the pipeline, including SillaJen/Transgene’s Pexa-Vec for liver cancer and other solid tumours with trial results due between now and the end of
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Health Psychologist, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Head of Health Psychology, London
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
- Scientists discover new approach to treat brain tumours
- Recognising HIV Vaccine Awareness Day
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- UICC launches global ATOM Coalition to increase access to essential cancer medicines
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- Live Webinar: The Future of MedTech: Streamlined Clinical Data Collection & Management
- Medscape: Connect to the conversation
- A Medscape 4-part video interview series
- Why big pharma needs to be braver
- MadMicrobe Studios Inc Announces New European Venture
- EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine
- Roche shares new positive Ocrevus data for MS patients
- First trial of a vaccine against Alzheimer’s launches
- Bristol Myers Squibb releases positive trial results for plaque psoriasis treatment
- MHRA approves Infex Therapeutics’s study for treatment for non-cystic fibrosis patients
- Creating an engaging experience for patients
- Mapping patient pathways – with a focus on patient-centricity
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- Why big pharma needs to be braver
- The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
